PFKFB3 and age-related macular degeneration: In a separate study pertaining to AMD, the targeting of PFKFB3 exhibited therapeutic effects by mitigating CNV damage and suppressing the activation of the inflammatory factor pathway [70], again verifying that controlling PFKFB3-mediated microglial activation is an effective treatment for AMD.